Adjuvant mFOLFIRINOX, New Standard of Care for Resectable Pancreatic Cancer

The most common treatment approach for patients with resectable pancreatic cancer is surgery, followed by six cycles of adjuvant chemotherapy with gemcitabine or, more recently, with gemcitabine/capecitabine in combination. Unfortunately, the majority of patients relapse within two years, highlighting a need for improved treatment options for early stage pancreatic cancer. At the 2018 American Society […]

Read More

Clinically Meaningful Progression-Free Survival Benefit With Ribociclib and Fulvestrant in Advanced HR-Positive Breast Cancer

In recent years, cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have become standard of care in combination with endocrine therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). Ribociclib is a CDK 4/6 inhibitor that has recently been approved, in combination with an aromatase inhibitor, for first-line […]

Read More

Practice-Changing Results From TAILORx Trial in Early Breast Cancer

For women with node-negative, hormonal receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, early breast cancer, the 21-gene recurrence score (RS) assay can be used to predict risk of recurrence and to tailor treatment. Patients with low RS (0-10) have low risk of recurrence when treated with endocrine therapy alone, while patients with high RS […]

Read More

Upfront Cytoreductive Nephrectomy Not Needed Before Targeted Therapy in mRCC

For patients with metastatic renal cell carcinoma (mRCC), initial treatment typically includes cytoreductive nephrectomy followed by angiogenesis inhibitor therapy. While retrospective analyses have historically shown that patients who receive a nephrectomy have prolonged survival compared to those who do not, no study has directly compared nephrectomy and targeted therapy in patients newly diagnosed with mRCC. […]

Read More

Optimizing Treatment for Patients With Relapsed Multiple Myeloma

Optimizing Treatment for Patients With Relapsed Multiple Myeloma At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, cutting edge research and paradigm-changing data were presented across different tumor types, including multiple myeloma. Some of the new findings from the phase III clinical trials in relapsed refractory multiple myeloma (RRMM) will likely impact current […]

Read More

Important New FDA Approvals in May for Patients With Cancer

Combo Dabrafenib/Trametinib for BRAF-Mutated Thyroid Cancer. The United States Food and Drug Administration (FDA) expanded the indication of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib (Tafinlar® and Mekinist®, Novartis) in combination to include use in patients with BRAFV600E-mutated anaplastic thyroid cancer. This approval was based on results from a multicohort, nonrandomized, phase II […]

Read More

2018 Oncology Annual Meeting Phase III Trial Data You Can’t Miss

The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting begins tomorrow at the McCormick Place Convention Center in Chicago, Illinois. More than 39,000 participants from around the world are expected to attend this meeting to share the latest advances in cutting edge oncology research and patient care over the next five days. The theme […]

Read More

High Major Pathologic Response With Neoadjuvant Nivolumab in Resectable NSCLC

Immunotherapies targeting PD-1 and PD-L1 have become standards-of-care across all lines of therapy for patients with metastatic non-small cell lung cancer (NSCLC) who do not have targetable driver mutations. Furthermore, the PD-L1 inhibitor durvalumab was recently approved as consolidation therapy after chemoradiation in locally advanced NSCLC.  Based on the improved outcomes seen with these agents […]

Read More

Immunoscore Reliable to Estimate Risk of Recurrence in Early CRC

Currently, the risk of recurrence after surgery for patients with colorectal cancer (CRC) is estimated based on histopathological criteria of tumor invasion according to the American Joint Committee on Cancer (AJCC) and TNM classification system and on features of tumor cell differentiation. In recent years, the role of the immune system in cancer patient outcomes […]

Read More

EMA-recommendations-primeoncology_2017

EMA Positive Opinions to Expand Oncology Treatment Options in Europe

In March and April 2018, the European Medicines Agency (EMA) issued several positive opinions that recommended approval or expanded indications for oncology/hematology agents. All but one of these agents has been previously approved by the US Food and Drug Administration (FDA) for similar indications. Osimertinib for First-Line EGFR-Mutant NSCLC. The EMA granted a positive opinion […]

Read More